-
-
-
-
-
-
-
Goldman Sachs Reiterates Sell Rating on Acadia Pharmaceuticals (ACAD)
-
-
-
-
-
-
-
Increasing unusual option volume: ACAD ALHC PLAY FPS ITUB NAVN WVE UAL XEL
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Raised to $37 at RBC Capital on 'Strong Sales'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
-
-
-
-
-
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
-
-
-
-
-
-
Acadia Pharma (ACAD) Tops Q4 EPS by 146c ; Offers Guidance
-
479,029 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


